Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 19/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 10/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 10/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6914248 | 0.93 | ADRB3 (0.53) | ADRB3ADRB1ADRB2 | |
| SCHEMBL6914158 | 0.89 | ADRB3 (0.52) | ADRB3ADRB1ADRB2CYP2D6ALDH1A1 | |
| SCHEMBL6914776 | 0.89 | ADRB3 (0.65) | ADRB3ADRB1ADRB2 | |
| SCHEMBL6913440 | 0.86 | ADRB3 (0.66) | ADRB3ADRB1ADRB2CYP2D6MEN1 | |
| SCHEMBL6914240 | 0.83 | ADRB3 (0.62) | ADRB3ADRB1ADRB2 | |
| SCHEMBL6907204 | 0.81 | ADRB3 (0.63) | ADRB3ADRB1ADRB2MEN1ALDH1A1 | |
| SCHEMBL6911769 | 0.79 | ADRB3 (0.54) | ADRB3ADRB1ADRB2 | |
| SCHEMBL6914156 | 0.79 | ADRB3 (0.67) | ADRB3ADRB1ADRB2 | |
| SCHEMBL6906589 | 0.77 | ADRB3 (0.52) | ADRB3ADRB1ADRB2 | |
| SCHEMBL7765020 | 0.77 | ADRB3 (0.55) | ADRB3ADRB1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242485-A1 | Compositions and methods for the amelioration of leptin resistance | KADOWAKI TAKASHI (JP) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242485-A1 | Compositions and methods for the amelioration of leptin resistance | ADIPOR1, FABP4, ADIPOR2 | ADRB3 6/4885ADRB1 11/4885ADRB2 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.